Boosting immunotherapy with low-dose liver radiation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with melanoma or non-small cell lung cancer and radiographic liver metastases will continue standard PD‑1/PD‑L1 immunotherapy (with or without standard chemotherapy) while receiving low‑dose liver radiation (LD‑LRT) before treatment cycles 1, 2, and 3. The study runs two parallel cohorts (NSCLC and melanoma) and uses Simon’s optimal two‑stage design to compare 6‑month progression‑free survival (PFS) in each cohort against historical benchmarks, targeting a 25% absolute improvement. The primary endpoint is 6‑month PFS evaluated separately for each cohort, and LD‑LRT is the only investigational intervention added to standard care. The trial is conducted at a single site (University of Cincinnati Medical Center) and will enroll patients who meet performance status and organ function criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. ECOG performance status ≤2 (or Karnofsky ≥60%, see Appendix A).
3. Patients must have adequate organ and marrow function to receive standard of care immunotherapy and/or chemoimmunotherapy as per the treating medical oncologist.
4. Must be planning to, and able to, undergo active treatment with PD-L1 or PD-1 checkpoint immunotherapy given per standard care throughout the duration of the RT intervention per their treating physician.

   • Note: Patients may receive other SOC CTLA 4 inhibitors or other SOC chemotherapy/immunotherapy in combination with a SOC PD-L1 or PD-1 checkpoint inhibitor and remain eligible.
5. Biopsy proven Non-Small Cell Lung Cancer (NSCLC) or Melanoma.
6. Radiographic evidence of liver metastases.
7. Women of child-bearing potential and men must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
8. Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
9. Patients must have insurance authorization to proceed with radiotherapy prior to initiation of radiation treatment on study

Exclusion Criteria:

1. Patients with prior immunotherapy use in the adjuvant setting for NSCLC or Melanoma are eligible unless the adjuvant immunotherapy was delivered within 6 months of enrollment.
2. Patients with NSCLC are ineligible for enrollment in cohort 1 if the presence of the following driver mutations are noted: EGFR, ALK, ROS1, RET.
3. Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous, in the opinion of the Investigator.
4. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen in the opinion of the Investigator.
5. Pregnant women are excluded from this study considering the use of ionizing radiation.

Where it's running

• University of Cincinnati Medical Center
  Cincinnati, Ohio, United States Recruiting

Study contacts

• Study coordinator: UCCC Clinical Trials Office
• Email: cancer@uchealth.com
• Phone: 513-584-7698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Subcutaneous versus intravenous immune therapy: which do patients prefer?

  This project will test whether patients with advanced cancers prefer subcutaneous (under‑the‑skin) versus intravenous nivolumab or, if available, pembrolizumab.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223424

• Urolithin A (MitoPure®) with immune checkpoint inhibitors for newly diagnosed solid tumors

  This trial tests whether taking urolithin A (MitoPure®) alongside first-line immune checkpoint inhibitor therapy changes immune responses in adults with newly diagnosed solid tumors.

  Recruiting Goethe University · Frankfurt · NCT07161310

• Testing AZD6750 safety in adults with selected advanced or metastatic solid tumors

  This trial tests whether AZD6750, a CD8-guided IL-2 medicine given alone or with other cancer drugs, is safe and how it behaves in adults with certain advanced or metastatic solid tumors.

  Recruiting at 13 sites Phase 1/2 AstraZeneca · Grand Rapids, Michigan and 12 other locations · NCT07115043

• GV20-0251 treatment for adults with advanced solid tumors

  This study will test GV20-0251 to see if it helps adults with advanced solid tumors that have stopped responding to approved therapies.

  Recruiting at 3 sites Phase 1/2 GV20 Therapeutics · Beijing, Beijing Municipality and 2 other locations · NCT07070518

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.